NEWS
Our Latest News
ARCHIMED MedTech sells orthopedic implants maker Citieffe to Poly Medicure, a leading global manufacturer of medical devices
Citieffe was the last investment in ARCHIMED’s MED I fund, now fully liquidated after generating 7.2 times investors’ money, or a 59 percent annual return over 11 years – the best performance of any 2014-vintage buyout fund.
ARCHIMED buys Cellese, a pioneering developer of growth factors and exosome-based skincare products
September
4,
2024
ARCHIMED acquires Irrimax, market leader in anti-microbial wound irrigation solutions
August
28,
2024
ARCHIMED concludes successfully its £203 million take-private bid for drug development software leader Instem
November
27,
2023
ARCHIMED creates a leading specialized dermatological-focused CRO via the simultaneous purchase & merger of Symbio and Proinnovera
November
17,
2023
ARCHIMED top-ranked buyout fund MED I earns 4.5x on the sale of Vita
October
27,
2023
368